The liver-targeted metabolic peptide — dual glucagon/GLP-1 agonist studied in hepatic models. 20+ peer-reviewed preclinical studies. 99%+ HPLC-verified purity. 3-lab independent COA on every batch.
Survodutide is a dual glucagon/GLP-1 receptor agonist — a next-generation metabolic peptide that simultaneously activates both the glucagon receptor and the GLP-1 receptor. This dual mechanism distinguishes it from single-receptor GLP-1 agonists like glp-1sm by adding glucagon receptor activation, which is particularly relevant to hepatic (liver) lipid metabolism research.
Preclinical and early clinical research has focused on survodutide's effects on metabolic pathway modulation, body composition, glucose homeostasis, and particularly its potential role in hepatic lipid metabolism models — including non-alcoholic steatohepatitis (NASH) research contexts. The dual-agonist approach represents an emerging frontier in metabolic peptide science.
Survodutide is classified as a research-use-only compound. It is not FDA-approved for any therapeutic indication. All references below describe preclinical (in vitro or animal model) research contexts, not human clinical outcomes.
The glucagon receptor component drives survodutide's liver-targeting research interest. Preclinical models examine its effects on hepatic fat reduction, lipid oxidation, and NASH-related endpoints — a key differentiator from GLP-1-only agonists.
Dual glucagon/GLP-1 activation creates a unique metabolic signaling profile. Studies examine survodutide's effects on energy expenditure, thermogenesis, and overall metabolic rate modulation in preclinical obesity models.
Preclinical research explores survodutide's effects on body weight, fat mass reduction, and lean mass preservation — examining whether the dual-agonist mechanism provides advantages over single-receptor approaches in body composition models.
GLP-1 receptor activation is well-established in glucose regulation research. Studies examine how survodutide's dual mechanism affects insulin sensitivity, glucose disposal, and glycemic control in metabolic disorder models.
Research-grade Survodutide with 3-lab COA verification is available at SMART MD Peptides in a 6mg formulation. Every batch is publicly verifiable at smartmdpeptides.com/verify.
GLP-1SM is a GLP-1-only receptor agonist. Survodutide is a dual glucagon/GLP-1 receptor agonist — it activates both receptors simultaneously. The glucagon receptor activation adds liver-targeting metabolic effects, making survodutide particularly interesting for hepatic lipid metabolism and NASH research models.
99%+ HPLC-verified purity. Each batch is independently verified by 3 U.S. laboratories — HPLC for purity, mass spectrometry for molecular weight, and LAL endotoxin assay for safety.
Lyophilized (unreconstituted) Survodutide should be stored at -20°C, protected from light and moisture. Once reconstituted, store at 2-8°C and use within the timeframe specified on your lot-specific documentation.
Check the COA before you buy. Compare it against any other supplier's documentation.